Related Experiment Video
Updated: Jul 25, 2026

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
Published on: June 15, 2011
Comprehensive analysis of thalassemia alleles (CATSA) based on third-generation sequencing is a comprehensive and
Ju Long1, Chunhui Yu2, Lei Sun1
1School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, China; Laboratory of Medical Genetics, Qinzhou Maternal and Child Health Care Hospital, Qinzhou, Guangxi 535099, China.
Insights
A novel method, CATSA, identified the most thalassemia variants in newborns compared to capillary electrophoresis and hotspot analysis. This advance supports China
Area of Science:
- Genetics
- Molecular Biology
- Public Health
Background:
- Thalassemia is a prevalent and severe monogenic disorder globally, stemming from alpha- or beta-globin gene variants.
- Current treatments for thalassemia are limited, emphasizing the need for effective prevention and control strategies.
Purpose of the Study:
- To evaluate the efficacy of hemoglobin capillary electrophoresis (CE), hotspot testing, and third-generation sequencing (TGS) for neonatal thalassemia screening.
- To assess the performance of CATSA (a novel method) in detecting thalassemia variants in newborns.
Main Methods:
- Analysis of 2000 newborn samples using CE, hotspot testing, and TGS.
- Comparative assessment of variant detection rates and types across different methods.
- Evaluation of CATSA's ability to determine the cis-trans relationship of variants.
Main Results:
- CATSA detected significantly more thalassemia variants (26.75%) than CE (12.45%) and hotspot analysis (21.2%).
- CATSA identified hotspot variants, copy number variations, rare pathogenic variants, and novel potentially disease-causing variants.
- CATSA accurately determined the cis-trans relationship of variants, reducing diagnosis time.
Conclusions:
- CATSA demonstrates superior performance in detecting thalassemia variants in neonates compared to existing methods.
- CATSA offers powerful technical support for China's three-tiered thalassemia prevention and control strategy.
- This method has the potential to improve early diagnosis and management of thalassemia.
Abstract:
Thalassemia is one of the most common and damaging monogenic diseases in the world. It is caused by pathogenic variants of α- and/or β-globin genes, which disrupt the balance of these two protein chains and leads to α-thalassemia or β-thalassemia, respectively. Patients with α-thalassemia or β-thalassemia could exhibit a severe phenotype, with no simple and effective treatment. A three-tiered strategy of carrier screening, prenatal diagnosis and newborn screening has been established in China for the prevention and control of thalassemia, of which the first two parts have been studied thoroughly. The implementation of neonatal thalassemia screening is lagging, and the effectiveness of various screening programs has not yet been demonstrated. In this study, hemoglobin capillary electrophoresis (CE), hotspot testing method, and third-generation sequencing (TGS) were used in the variant detection of 2000 newborn samples, to assess the efficacy of these methods in neonatal thalassemia screening. Compared with CE (249, 12.45 %) and hotspot analysis (424, 21.2 %), CATSA detected the largest number of thalassemia variants (535, 26.75 %), which included 24 hotspot variants, increased copy number of α-globin gene, rare pathogenic variants, and three unreported potentially disease-causing variants. More importantly, CATSA directly determined the cis-trans relationship of variants in three newborns, which greatly shortens the clinical diagnosis time of thalassemia. CATSA showed a great advantage over other genetic tests and could become the most powerful technical support for the three-tiered prevention and control strategy of thalassemia.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets

